BioNTech of Germany and the US pharmaceutical giant Pfizer reported positive preliminary results on Wednesday from a joint project to develop a coronavirus vaccine. Known as BNT162b1, it produces antibody responses at or above the levels seen in any convalescent serum — blood from people who have recovered — at relatively low doses, according to BioNTech CEO Ugur Sahin. The preliminary data come from a so-called phase 1/2 trial that aimed to show the vaccine is not toxic and triggers an immune system response to prepare the body to fight off the virus.
Related Posts
